Therefore, the results reported by Hong et al. [229] appear very encouraging, as they indicate that As2O3 might be exploited as a new therapeutic strategy for targeting non-APL patients in combination with dual PI3K/mTOR inhibitors. The gene discussed is PIK3CD; the disease is acute promyelocytic leukemia.